Dariohealth Has Acquired Twill, To Create Comprehensive Digital Offerings For Chronic Conditions; Dario Paid $10M In Cash And Agreed To Issue Approximately 10M Shares In The Form Of Pre-funded Warrants
Portfolio Pulse from Benzinga Newsdesk
DarioHealth Corp. has acquired Twill, aiming to enhance its digital offerings for chronic conditions. The acquisition, valued at $10M in cash plus around 10M pre-funded warrants in shares, is expected to nearly double Dario's pro forma revenues in 2023. This strategic move is immediately accretive to revenue and gross margins, and is anticipated to accelerate Dario's path to profitability.
February 21, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DarioHealth's acquisition of Twill for $10M in cash and 10M pre-funded warrants is expected to significantly boost its 2023 pro forma revenues and improve gross margins, accelerating its profitability.
The acquisition of Twill by DarioHealth is a significant strategic move, directly impacting DarioHealth's financial outlook and market positioning. The deal's immediate accretion to revenue and gross margins, along with the expected doubling of pro forma revenues in 2023, suggests a positive short-term impact on DarioHealth's stock price. The confidence level reflects the clear financial benefits outlined, though market reactions can be unpredictable.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100